Estimation of the major cardiovascular events prevention with Inclisiran. (November 2020)

• Record Type: Journal Article
• Authors: Cordero, Alberto; Santos-Gallego, Carlos G.; Fácila, Lorenzo; Rodríguez-Mañero, Moisés; Bertomeu-González, Vicente; Castellano, Jose M; Seijas-Amigo, José; Núñez, Julio; Zuazola, Pilar; González-Juanatey, Jose R.; Badimon, Juan J.
• Is Part Of: Atherosclerosis. Volume 313(2020)
• Page Start: 76
• Page End: 80
• Publication Date: 2020-11
• Subjects: Inclisiran -- PCSK9 -- LDLc -- MACE; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2020.09.021
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: The ORION 10–11 trials have reported the efficacy of Inclisiran on low-density lipoprotein cholesterol (LDLc) reduction, and also suggested prevention of major cardiovascular events (MACE) incidence. Methods: We have performed a meta-analysis of the available studies, involving PCSK9 inhibitors or Inclisiran for >6 months, that reported the incidence of MACE. The primary endpoint was MACE incidence, as reported in outcomes-based randomized clinical trials (OB-RCT) and non OB-RCT. Analyses were performed using fixed effect models and fractional polynomial regression. Results: The meta-analysis included a total of 57, 431 patients, 1592 treated with Inclisiran and 28, 259 with PSCK9 inhibitors (17, 244 with evolocumab and 11, 015 with alirocumab). Baseline mean LDLc was 104.1 (12.9) mg globally. On-treatment mean LDLc was 40.1 (7.8) mg/dl and mean absolute LDLc reduction was 60.6 (10.3) mg/dl. A total of 5389 MACE were reported, 2482 in patients receiving the study drug and 2907 in patients assigned to placebo. Treatment was associated with OB-RCT and no heterogeneity was observed. The estimation of MACE reduction associated with LDLc reduction, adjusted by age, diabetes, hypertension and baseline LDLc, provided a linear trend in the risk of MACE and LDLc reduction that was linear and all studies fitted properly. Conclusions: The results of the ORION 10–11 trials are in concordance with results of trials involving treatment with PCSK9 inhibitors. The results of the ORION-4 trial will provide definite evidence on the effects of Inclisiran on MACE reduction. Graphical abstract: Image 1 Highlights: The ORION 10–11 trials have reported the efficacy of Inclisiran on LDLc reduction. We performed a meta-analysis with studies involving PCSK9 inhibitors >6 months or Inclisiran. Treatment was associated with 15% MACE incidence compared to placebo. No heterogeneicity between studies was found. The results of the ORION 10–11 trials are in concordance with results of trials involving PCSK9 inhibitors.